机构：[1]Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China[2]Institute of Respiratory Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China[3]Department of Respiratory and Critical Care Medicine, Tongren Hospital Affiliated to Wuhan University, The Third Hospital of Wuhan, Wuhan, People’s Republic of China
Purpose: The mechanism of lung cancer (LC) in male patients with chronic obstructive pulmonary disease (COPD) has not been well understood, and the early diagnosis is currently challenging. The study aimed to explore the association of DNA methylation levels with LC development in male COPD patients.Patients and Methods: A total of 147 male participants were divided into four groups, ie, COPD+LC group, COPD group, LC group, and control (CON) group. The methylation levels of human serine protease inhibitor A1 (SERPINA1) and the serum levels of inflammatory biomarkers were compared among groups. Multivariate logistic regression was performed to explore the correlation of inflammatory biomarkers and gene methylation with lung cancer combining COPD.Results: SERPINA1 methylation levels were significantly higher in the COPD+LC group than that in the COPD group and LC group, respectively (all p < 0.05). The serum levels of interleukin (IL)-1 beta, IL-17, and transforming growth factor (TGF)-beta 1 were significantly higher in the COPD+LC group than in the LC group (all p < 0.05). The SERPINA1 methylation levels were positively correlated with the IL-1 beta levels (r = 0.5188, p = 0.0012). The AUC (area under curve) of SERPINA1 methylation for the diagnosis of LC in COPD was 0.677 (sensitivity of 52.2% and specificity of 78.2%).Conclusion: The methylation of SERPINA1 is linked to LC in patients with COPD. The SERPINA1 methylation levels were positively correlated with the IL-1 beta levels. These findings may be of diagnostic value.
基金：
National Key R&D Program of China [2018YFC1311900]; National Natural Science Foundation of China [81570082, 81770084]; Shanghai Municipal Key Clinical Specialty [shslczdzk02202]; Shanghai Top -Priority Clinical Key Disciplines Construction Project [2017ZZ02014]; Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases [20dz2261100]; Cultivation Project of Shanghai Major Infectious Disease Research Base [20dz2210500]
第一作者机构：[1]Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China[2]Institute of Respiratory Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
通讯作者：
通讯机构：[1]Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China[2]Institute of Respiratory Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China[*1]Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, 200025, People’s Republic of China,
推荐引用方式(GB/T 7714)：
Zhang Li Yue,Sun Xian Wen,Ding Yong Jie,et al.SERPINA1 Methylation Levels are Associated with Lung Cancer Development in Male Patients with Chronic Obstructive Pulmonary Disease[J].INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.2022,17:2117-2125.doi:10.2147/COPD.S368543.
APA：
Zhang, Li Yue,Sun, Xian Wen,Ding, Yong Jie,Yan, Ya Ru,Li, Chuan Xiang...&Li, Qing Yun.(2022).SERPINA1 Methylation Levels are Associated with Lung Cancer Development in Male Patients with Chronic Obstructive Pulmonary Disease.INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,17,
MLA：
Zhang, Li Yue,et al."SERPINA1 Methylation Levels are Associated with Lung Cancer Development in Male Patients with Chronic Obstructive Pulmonary Disease".INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 17.(2022):2117-2125
